Cannabis and mental illness : a review Darby J. E. Lowe · Julia D. Sasiadek · Alexandria S. Coles · Tony P. George European Archives of Psychiatry and Clinical Neuroscience, 2018, 1-14. Doi : 10.1007/s00406-018-0970-7 Abstract With the increasing push to legalize cannabis in Western nations, there is a need to gage the potential impact of this policy change on vulnerable populations, such as those with mental illness, including schizophrenia, mood, and anxiety disorders. This is particularly important as there are strong motives in these individuals to seek short-term reward (e.g., “getting high”). Nonetheless, data to support the beneficial effects of cannabis use in psychiatric [...]
Lire la suiteSupporting Future Cannabis Policy – Developing a Standard Joint Unit : A Brief Back-Casting Exercise. Hugo López-Pelayo, Silvia Matrai, Mercè Balcells-Olivero, Eugènia Campeny, Fleur Braddick, Matthijs G. Bossong, Olga S. Cruz, Paolo Deluca, Geert Dom, Daniel Feingold, Tom P. Freeman, Pablo Guzman, Chandni Hindocha, Brian C. Kelly, Nienke Liebregts, Valentina Lorenzetti, Jakob Manthey, João Matias, Clara Oliveras, Maria Teresa Pons, Jürgen Rehm, Moritz Rosenkranz, Zoe Swithenbank, Luc van Deurse, Julian Vicente, Mike Vuolo, Marcin Wojnar and Antoni Gual Frontiers in Psychiatry, 2021, 12, 675033. doi : 10.3389/fpsyt.2021.675033 The standardization of cannabis doses is a priority for research, policy-making, clinical and harm-reduction interventions and consumer security. Scientists [...]
Lire la suiteAttitudes Toward the Use of Medical Cannabis and the Perceived Efficacy, Side-effects and Risks : A Survey of Patients, Nurses and Physicians Neta HaGani, Sharon Sznitman, Michael Dor, Gil Bar-Sela, Dana Oren, Lilia Margolis-Dorfman, Itay Goor-Aryeh & Manfred S. Green Journal of Psychoactive Drugs, 2021, 1-10. Doi : 10.1080/02791072.2021.2009598 ABSTRACT Gaps between physician and patient perceptions may lead to misunderstandings and mismanage of treatment. There are sparse data about the differences in opinions toward medical cannabis (MC) between patients and health professionals. The aim of this study was to examine the attitudes toward MC, its perceived efficacy, side effects and risk of dependency, among patients, [...]
Lire la suiteCannabis Domestication, Breeding History, Present-day Genetic Diversity, and Future Prospects Robert C. Clarke and Mark D. Merlin CRITICAL REVIEWS IN PLANT SCIENCES, 2016, VOL. 35, NOS. 5–6, 293–327 Doi : 10.1080/07352689.2016.1267498 ABSTRACT Humans and the Cannabis plant share an intimate history spanning millennia. Humans spread Cannabis from its Eurasian homelands throughout much of the world, and, in concert with local climatic and human cultural parameters, created traditional landrace varieties (cultivars resulting from a combination of natural and farmer selection) with few apparent signs of domestication. Cannabis breeders combined populations from widely divergent geographical regions and gene pools to develop economically valuable fiber, seed, and drug cultivars, [...]
Lire la suiteBirth Outcomes of Neonates Exposed to Marijuana in Utero. A Systematic Review and Meta-analysis Greg Marchand, MD; Ahmed Taher Masoud, MD; Malini Govindan, MD; KellyWare, MS; Alexa King, BS; Stacy Ruther, BS; Giovanna Brazil, BS; Hollie Ulibarri, BS; Julia Parise, BS; Amanda Arroyo, BS; Catherine Coriell, BS; Sydnee Goetz, BS; Amitis Karrys, BS; Katelyn Sainz, MD JAMA Network Open, 2022, 5, (1), e2145653, 1-13. doi : 10.1001/jamanetworkopen.2021.45653 Abstract IMPORTANCE While some studies have found an association between marijuana use and adverse neonatal outcomes, results have not been consistent across all trials. OBJECTIVE To assess available data on neonatal outcomes in marijuana-exposed pregnancies. DATA SOURCES PubMed, Medline, ClinicalTrials.gov, [...]
Lire la suiteEDITORIAL : Cannabinoids in psychiatry : they are here to stay Julia Jiyeon Woo, Emma van Reekum, Sagnik Bhattacharyya and Zainab Samaan The British Journal of Psychiatry, 2022, 1-3. doi : 10.1192/bjp.2021.216 Summary Cannabinoids are commonly perceived by the public as safe and effective for improving mental health, despite limited evidence to support their use. We discuss reasons why cannabinoids may be particularly compelling for our patients and provide strategies for how psychiatrists can counsel and educate patients on the evidence regarding cannabinoids. Keywords : Cannabis; drug interactions and side-effects; drugs of dependence disorders; marijuana; education and training. Vignette A young man sits in his psychiatrist’s office. After [...]
Lire la suiteCannabinoids, Pain, and Opioid Use Reduction : The Importance of Distilling and Disseminating Existing Data Kent E. HUTCHISON, Sarah L. HAGERTY, Jeffrey GALINKIN, Angela D. BRYAN, L. Cinnamon BIDWELL Cannabis and Cannabinoid Research, 2019, 4, (3), 158-164. Doi : 10.1089/can.2018.0052 Abstract The high prevalence of chronic pain conditions combined with an over-reliance on opioid prescriptions has resulted in an opioid epidemic and a desperate need for solutions. There is some debate about whether cannabis might play a role in addressing chronic pain conditions as well as the opioid epidemic. Recent surveys suggest that a large number of people are using cannabis as a treatment for [...]
Lire la suiteL’INDISPENSABLE SUR... LE CANNABIDIOL (CBD) MILDECA Mission interministérielle de lutte contre les drogues et les conduites addictives 2021 Qu’est-ce que le cannabidiol ? C’est : une des principales substances actives de type cannabinoïde de la plante de chanvre, au même titre que le THC (delta-9-tétrahydrocannabinol). On la trouve principalement au niveau de la fleur et des feuilles adjacentes. un composant, sous forme d’extrait, de médicaments ou de produits de consommation courante, dont seuls certains sont autorisés en France. Ce n’est pas : un stupéfiant. Le CBD reste tout de même une substance à effet psychoactif, qui peut avoir des interactions avec d'autres molécules, notamment des médicaments. une [...]
Lire la suiteMedical cannabis authorization and the risk of cardiovascular events : a longitudinal cohort study Arsene Zongo, Cerina Lee, Jason R. B. Dyck, Jihane El‑Mourad, Elaine Hyshka, John G. Hanlon and Dean T. Eurich BMC Cardiovascular Disorders, 2021, 21, 426 doi : 10.1186/s12872-021-02229-6 Abstract Background : Cannabis is increasingly used for therapeutic purpose. However, its safety profile is not well known. This study assessed the risk of cardiovascular-related emergency department (ED) visit and hospitalization in adult patients authorized to use medical cannabis in Ontario, Canada from 2014 to 2017. Methods : This is a longitudinal cohort study of patients who received medical cannabis authorization and followedup in [...]
Lire la suiteScoping Review and Meta-Analysis Suggests that Cannabis Use May Reduce Cancer Risk in the United States Thomas M. Clark Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 413-434. Doi : 10.1089/can.2019.0095 Abstract Introduction:Cannabis smoke contains carcinogens similar to tobacco, in addition to compounds with antitumor activity. Cannabis use reduces the risk of obesity and cannabinoids inhibit chronic inflammation, known causes of cancer. The net effect of Cannabis use on cancer risk is not known. Objective: To examine the association between Cannabis use and cancer risk in the United States. Methods: Identify and analyze published data on cancer risk in Cannabis users. Results: A total of 55 data [...]
Lire la suite